Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS - PubMed (original) (raw)
Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS
K Makhlouf et al. J Neuroimmunol. 2001.
Abstract
Interleukin (IL)-12 is a cytokine thought to play a major role in the pathogenesis of multiple sclerosis (MS). We have previously shown that patients with progressive MS have a high percentage of IL-12-producing monocytes in the blood compared to normal individuals. We analyzed 269 blood samples from 189 MS patients for the percentage of IL-12-producing monocytes. We found that the increased IL-12 expression correlates with disability, as measured by the Expanded Disability Status Scale (EDSS), and with disease activity, measured by the presence of gadolinium-enhancing magnetic resonance imaging (MRI) lesions.
Similar articles
- Impaired interleukin-12 production in multiple sclerosis patients.
Rohowsky-Kochan C, Molinaro D, Choudhry A, Kahn M, Cook SD. Rohowsky-Kochan C, et al. Mult Scler. 1999 Oct;5(5):327-34. doi: 10.1177/135245859900500505. Mult Scler. 1999. PMID: 10516776 - Increased release of interleukin-12p40 in MS: association with intracerebral inflammation.
Fassbender K, Ragoschke A, Rossol S, Schwartz A, Mielke O, Paulig A, Hennerici M. Fassbender K, et al. Neurology. 1998 Sep;51(3):753-8. doi: 10.1212/wnl.51.3.753. Neurology. 1998. PMID: 9748022 - Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP. Scott LJ, et al. CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review. - Reduced prevalence of allergic disease in patients with multiple sclerosis is associated with enhanced IL-12 production.
Tang L, Benjaponpitak S, DeKruyff RH, Umetsu DT. Tang L, et al. J Allergy Clin Immunol. 1998 Sep;102(3):428-35. doi: 10.1016/s0091-6749(98)70131-9. J Allergy Clin Immunol. 1998. PMID: 9768584 - MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS).
Barkhof F. Barkhof F. Mult Scler. 1999 Aug;5(4):283-6. doi: 10.1177/135245859900500415. Mult Scler. 1999. PMID: 10467389 Review.
Cited by
- Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response.
Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S. Graber JJ, et al. J Neuroimmunol. 2007 Apr;185(1-2):168-74. doi: 10.1016/j.jneuroim.2007.01.011. Epub 2007 Feb 27. J Neuroimmunol. 2007. PMID: 17328965 Free PMC article. Clinical Trial. - Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis.
Bakshi R, Yeste A, Patel B, Tauhid S, Tummala S, Rahbari R, Chu R, Regev K, Kivisäkk P, Weiner HL, Quintana FJ. Bakshi R, et al. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e200. doi: 10.1212/NXI.0000000000000200. eCollection 2016 Apr. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 26894204 Free PMC article. - Inflammation in multiple sclerosis.
Haase S, Linker RA. Haase S, et al. Ther Adv Neurol Disord. 2021 Apr 16;14:17562864211007687. doi: 10.1177/17562864211007687. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33948118 Free PMC article. Review. - Myeloid cells - targets of medication in multiple sclerosis.
Mishra MK, Yong VW. Mishra MK, et al. Nat Rev Neurol. 2016 Sep;12(9):539-51. doi: 10.1038/nrneurol.2016.110. Epub 2016 Aug 12. Nat Rev Neurol. 2016. PMID: 27514287 Review. - Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis.
Kölliker Frers RA, Otero-Losada M, Kobiec T, Udovin LD, Aon Bertolino ML, Herrera MI, Capani F. Kölliker Frers RA, et al. Front Immunol. 2022 Jul 28;13:912005. doi: 10.3389/fimmu.2022.912005. eCollection 2022. Front Immunol. 2022. PMID: 35967312 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical